TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12821730
Drug: Insulin (1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin (1.0 mU x kg(‐1) x min(‐1)) plus dextrose to maintain euglycemia
Study: 10587317
Drug: Danish vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Danish vaccine (normal dose, 0.05 ml) given to neonates at birth
Study: 10587317
Drug: Danish vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Danish vaccine (half the normal dose) given at birth
Study: 10587317
Drug: IRP vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IRP vaccine given at birth at normal infant dose
Study: 10587317
Drug: Danish vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Danish vaccine (normal infant dose) given at 3 months of age
Study: 8561341
Drug: 0.9% sodium
Normalized name: LMD with 0.9% Sodium Chloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% sodium chloride solution (Control)
Study: 1670113
Drug: L-PAM (melphalan)
Normalized name: L-PAM
DrugBank: Melphalan (DB01042)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: L-PAM (melphalan) or L-PAM plus fluorouracil
Study: 6120059
Drug: 7.5 mg
Normalized name: biotin 7.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.5 mg CZP nightly with no antacid
Study: 6120059
Drug: CZP nightly
Approvals — FDA: no, EMA: no, PMDA: no
Description: CZP nightly for 30 ml Maalox
Study: 6120059
Drug: CZP nightly
Approvals — FDA: no, EMA: no, PMDA: no
Description: CZP nightly with Maalox with an additional 30 ml Maalox three times daily
Study: 6120059
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no antacid)
Study: 30224529
Drug: Chinfloxacin 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chinfloxacin 400 mg
Study: 30224529
Drug: Chinfloxacin 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chinfloxacin 600 mg
Study: 30224529
Drug: Chinfloxacin (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chinfloxacin (single and multiple doses)
Study: 21862748
Drug: Anti-IL-12/23 therapies
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-IL-12/23 therapies (ustekinumab and briakinumab)
Study: 21862748
Drug: Anti-TNF-α agents
Normalized name: Anti Bac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-TNF-α agents (adalimumab, etanercept, infliximab)
Study: 21862748
Drug: Placebo (for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (for anti-IL-12/23 therapies)
Study: 21862748
Drug: Placebo (for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (for anti-TNF-α agents)
Study: 19065858
Drug: Repetition condition
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repetition condition (same emotional face image presented twice)
Study: 14651700
Drug: Listening to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Listening to music for 20 minutes daily
Study: 14651700
Drug: Sitting quietly
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sitting quietly for 20 minutes daily (Control)
Study: 10981543
Drug: Combination diet
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination diet rich in fruits, vegetables, low-fat dairy, whole grains, fish, poultry, and nuts; reduced in fats, red meats, sweets, and sugar-containing beverages for 8 weeks
Study: 9601228
Drug: Myofunctional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Myofunctional therapy and orthodontic appliances (e.g., activators)
Study: 24875194
Drug: Losartan 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan 0.1 mg/kg per day
Study: 24875194
Drug: Losartan 0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan 0.3 mg/kg per day
Study: 24875194
Drug: Losartan 0.7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan 0.7 mg/kg per day
Study: 24875194
Drug: Losartan (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan (up to 1.4 mg/kg per day)
Study: 21810842
Drug: Aspirin taken
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin taken in the evening for 1 month
Study: 21810842
Drug: Aspirin taken
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin taken in the morning for 1 month
Study: 21810842
Drug: Aspirin taken
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin taken in the evening
Study: 21810842
Drug: Aspirin taken
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin taken in the morning
Study: 19952833
Drug: Yoga therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yoga therapy (YG)
Study: 15892268
Drug: Traditional Chinese
Normalized name: BORNEOL 1 g in 6.5 g / MINT 1 g in 6.5 g / ANGELICA DAHURICA ROOT 0.5 g in 6.5 g TOPICAL POWDER [Traditional Chinese Medicine Health Card and TCM Epidemic Prevention Card]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional Chinese Medicine (TCM) intervention
Study: 10720532
Drug: OspA vaccine
Normalized name: OspA protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: OspA vaccine recipients
Study: 10720532
Drug: OspA vaccine
Normalized name: OspA protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: OspA vaccine recipients with Lyme disease
Study: 7559202
Drug: Rufloxacin 400
Normalized name: ofloxacin 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rufloxacin 400 mg
Study: 30223226
Drug: Fulvestrant plus
Normalized name: Fulvestrant
DrugBank: Fulvestrant (DB00947)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Fulvestrant plus goserelin (F + G)
Study: 30223226
Drug: Anastrozole plus
Normalized name: Anastrozole
DrugBank: Anastrozole (DB01217)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Anastrozole plus goserelin (A + G)
Study: 30223226
Drug: Goserelin (G)
DrugBank: Goserelin (DB00014)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Goserelin (G) alone
Study: 16221299
Drug: Problem Solving
Normalized name: Solv X
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Problem Solving Treatment (PST) provided by nurses
Study: 12099989
Drug: Neoral oral
Normalized name: Neoral Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoral oral solution diluted in apple juice
Study: 12099989
Drug: Neoral oral
Normalized name: Neoral Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoral oral solution diluted in tap water
Study: 8071496
Drug: Moderate diet
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate diet (1.3 g protein/kg/day, 16-20 mg phosphorus/kg/day)
Study: 8071496
Drug: Low diet
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low diet (0.575 g protein/kg/day, 5-10 mg phosphorus/kg/day)
Study: 8071496
Drug: Very low
Normalized name: Very low fat spread
Approvals — FDA: no, EMA: no, PMDA: no
Description: Very low diet with keto or amino acids (0.28 g protein/kg/day, 4-9 mg phosphorus/kg/day)
Study: 3378276
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of gentamicin and methicillin
Study: 3378276
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of gentamicin and cloxacillin
Study: 3378276
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of clindamycin and mezlocillin
Study: 31113531
Drug: Surgeon's preference
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgeon's preference (e.g. fistulotomy, cutting seton, advancement flap, LIFT procedure)
Study: 10704632
Drug: Simvastatin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin (10 mg)
Study: 27276165
Drug: Naproxen (250mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naproxen (250mg TID for 10 days) and physical therapy
Study: 15898434
Drug: Erythromycin stinoprate
Normalized name: erythromycin stinoprate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin stinoprate capsules 250 mg
Study: 15898434
Drug: Erythromycin stinoprate
Normalized name: erythromycin stinoprate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin stinoprate capsules 500 mg
Study: 15898434
Drug: Erythromycin stinoprate
Normalized name: erythromycin stinoprate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin stinoprate capsules 750 mg
Study: 12480357
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (250 mg prednisolone reduced by 25 mg per day, 500 mL 6% hydroxyethyl starch, 400 mg pentoxifylline per day)
Study: 9659643
Drug: rHuEPO (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: rHuEPO (300 U/kg per dose, twice a week)
Study: 7858363
Drug: Epidural morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural morphine (2 mg in 3 ml saline) administered before the onset of pain (Group B)
Study: 7858363
Drug: Epidural saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural saline (3 ml) administered before the onset of pain (Group A)
Study: 7858363
Drug: Epidural morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural morphine (2 mg in 3 ml saline) administered after the onset of pain (Group B)
Study: 2576663
Drug: Somatostatin infusion
Normalized name: somatostatin
DrugBank: Somatostatin (DB09099)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Somatostatin infusion (250 micrograms/h in 100 ml saline)
Study: 31553469
Drug: Light therapy
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Light therapy plus CBT
Study: 31553469
Drug: Sham therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham therapy plus CBT
Study: 25261425
Drug: Combined group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined group (electrical stimulation and low-level laser therapy)
Study: 25261425
Drug: Laser group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laser group (low-level laser therapy dose of 4-6 J per point, six points at the knee joint)
Study: 24195208
Drug: Electroacupuncture treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electroacupuncture treatment with disperse-dense wave applied at specific acupuncture points (Taiyang, Xiaguan, Heliao)
Study: 22053565
Drug: Intravitreal Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravitreal Bevacizumab (IVB) 1.25 mg/0.05 ml
Study: 22053565
Drug: Intravitreal Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravitreal Bevacizumab and Triamcinolone (IVB/IVT) 1.25 mg/0.05 ml and 2 mg/0.05 ml
Study: 19447807
Drug: Optimized anti-arrhythmic
Normalized name: Anti Bac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimized anti-arrhythmic drug (AAD) therapy
Study: 9443527
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg dose of diazepam
Study: 8504712
Drug: Transdermal estrogen
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal estrogen patches (0.05 mg daily estradiol) with medroxyprogesterone acetate (5 mg orally for 14 days per month)
Study: 8504712
Drug: Calcium group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium group (500 mg calcium daily)
Study: 8504712
Drug: Transdermal estrogen
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal estrogen vs. calcium
Study: 3673928
Drug: 65 mg/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 65 mg/d AA intake for 2 weeks
Study: 3673928
Drug: 5 mg/d
Normalized name: Arixtra 5 mg/dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg/d AA intake for 4 weeks
Study: 3673928
Drug: 605 mg/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 605 mg/d AA intake for 3 weeks
Study: 3673928
Drug: 5 mg/d
Normalized name: Arixtra 5 mg/dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg/d AA intake for 4 days
Study: 3673928
Drug: 605 mg/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 605 mg/d AA intake for 4 days
Study: 3673928
Drug: 65 mg/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 65 mg/d AA intake for 3 days
Study: 3673928
Drug: AA intake
Approvals — FDA: no, EMA: no, PMDA: no
Description: AA intake calculated to maintain plasma AA levels of at least 0.4 mg/dL (23 mumol/L)
Study: 29300728
Drug: Intensive insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive insulin treatment (IIT)
Study: 23828313
Drug: Topical nasal
Normalized name: Nasal Inhalant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical nasal anesthetic (TNA)
Study: 20224514
Drug: Fixed-dose mycophenolate
Normalized name: mycophenolate
DrugBank: Mycophenolic acid (DB01024)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fixed-dose mycophenolate mofetil (MMF)
Study: 18641546
Drug: Tacrolimus treatment
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tacrolimus treatment
Study: 1850946
Drug: Oral diazepam,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral diazepam, 5 mg
Study: 1850946
Drug: Oral diazepam,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral diazepam, 10 mg
Study: 1850946
Drug: Oral midazolam,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral midazolam, 15 mg
Study: 6786536
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg of folic acid a day before and during early pregnancy
Study: 31415123
Drug: Long-term low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Long-term low-dose clarithromycin (CAM) therapy
Study: 31415123
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no clarithromycin therapy)
Study: 26073493
Drug: Lanreotide (90
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lanreotide (90 mg every 4 weeks) for 6 months
Study: 23147275
Drug: Beating Heart
Normalized name: porcine heart preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beating Heart Problems programme (8-week group programme based on cognitive behaviour therapy and motivational interviewing)
Study: 22703478
Drug: Carvedilol (12.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carvedilol (12.5 mg)
Study: 11757472
Drug: Nebivolol (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebivolol (5 mg)
Study: 17336229
Drug: Metoclopramide (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoclopramide (10 mg intravenously three times daily for 5 days)
Study: 17336229
Drug: Control (saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (saline administered in equal volume)
Study: 15111377
Drug: Transdermal testosterone
Normalized name: testosterone Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal testosterone (4 mg/patch) twice weekly for 6 months
Study: 2184564
Drug: Cisplatin alone,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin alone, modified MVAC scheme, or combination of cisplatin and methotrexate (3 cycles)
Study: 22216504
Drug: Frusemide (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Frusemide (120 mg daily)
Study: 30658699
Drug: Treatment escalation
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment escalation (initial prednisone and methotrexate, changed every 4 months)
Study: 30658699
Drug: Treatment tapering
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment tapering (tapering MTX)
Study: 30658699
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment (no DFR)
Study: 30658699
Drug: Drug-free remission
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Drug-free remission (DFR)
Study: 28298021
Drug: Parenteral nimodipine
Normalized name: Nimodipine
DrugBank: Nimodipine (DB00393)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Parenteral nimodipine (1-2 mg/hour) and hydroxyethyl starch (HES) from the day before surgery until the 7th postoperative day
Study: 28298021
Drug: Parenteral nimodipine
Normalized name: Nimodipine
DrugBank: Nimodipine (DB00393)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Parenteral nimodipine and HES
Study: 1108694
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no prophylactic treatment)
Study: 23343649
Drug: Continuous tranexamic
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuous tranexamic acid (TA) dosing: 10 mg/kg followed by an infusion of 1 mg·kg·h(‐1) throughout the operation, and 10 mg/kg into the CPB.
Study: 23343649
Drug: Discontinuous tranexamic
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Discontinuous tranexamic acid (TA) dosing: 10 mg/kg, then 10 mg/kg into the CPB and 10 mg·kg·h(‐1) at the end of CPB.
Study: 28262529
Drug: Intravenous neostigmine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous neostigmine 2.5mg
Study: 28262529
Drug: Intravenous metoclopramide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous metoclopramide 20mg
Study: 28262529
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of neostigmine and metoclopramide
Study: 18688808
Drug: Naltrexone (opiate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naltrexone (opiate blocker) administered in a double-blind, crossover design for 7 weeks with an additional 14 hr/week of observation
Study: 12551734
Drug: Lavandula tincture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lavandula tincture (1:5 in 50% alcohol) 60 drops/day plus placebo tablet (Group A)
Study: 12551734
Drug: Imipramine 100
Normalized name: trimipramine 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imipramine 100 mg/day plus placebo drop (Group B)
Study: 12551734
Drug: Imipramine 100
Normalized name: trimipramine 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imipramine 100 mg/day plus lavandula tincture 60 drops/day (Group C)
Study: 10546926
Drug: filgrastim (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: filgrastim (all doses)
Study: 6838746
Drug: Intraoperative methadone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraoperative methadone 10 mg i.v. at induction of anaesthesia
Study: 6838746
Drug: Postoperative methadone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative methadone 10 mg i.v. following operation
Study: 27734219
Drug: Acetaminophen 650
Normalized name: acetaminophen 650 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen 650 mg plus caffeine 65 mg (test)
Study: 27734219
Drug: Acetaminophen 650
Normalized name: acetaminophen 650 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen 650 mg (reference)
Study: 22505700
Drug: Double filtration
Normalized name: SNAIL SECRETION FILTRATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double filtration plasmapheresis (DFPP) in combination with leflunomide and methotrexate (MTX)
Study: 18041488
Drug: Doxepin 3
Normalized name: doxepin 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxepin 3 mg
Study: 18041488
Drug: Doxepin 1
Normalized name: doxepin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxepin 1 mg
Study: 21102997
Drug: Doxepin 1
Normalized name: doxepin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxepin 1 mg and 3 mg
Study: 12641399
Drug: SP monotherapy
Normalized name: SPS
Approvals — FDA: no, EMA: no, PMDA: no
Description: SP monotherapy
Study: 12641399
Drug: SP/CQ combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: SP/CQ combination therapy
Study: 12641399
Drug: SP/AQ combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: SP/AQ combination therapy
Study: 10462143
Drug: Cilnidipine (CNP)
Normalized name: cilnidipine
DrugBank: Cilnidipine (DB09232)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cilnidipine (CNP) 10 mg/day
Study: 7607610
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human growth hormone administration
Study: 2088249
Drug: Mefenamic acid
Normalized name: Mefenamic Acid
DrugBank: Mefenamic acid (DB00784)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mefenamic acid (500 mg orally, 8 hourly)
Study: 2088249
Drug: Control (placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (placebo tablet thrice daily)
Study: 41544
Drug: Temazepam 30
Normalized name: temazepam 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Temazepam 30 mg at night
Study: 31751687
Drug: Inonotus obliquus
Normalized name: Inonotus obliquus fruiting body
DrugBank: Inonotus obliquus fruiting body (DB14332)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inonotus obliquus polysaccharides (IOP) at a dosage of 50 mg/kg
Study: 31751687
Drug: Compound C
Normalized name: Compound cooking fat
DrugBank: Dorsomorphin (DB08597)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Compound C (chemical inhibitor of AMPK)
Study: 31374046
Drug: Escitalopram (or
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escitalopram (or another antidepressant) for 4 weeks after initial treatment
Study: 22520627
Drug: Essential oil
Normalized name: Essential oil
DrugBank: Rosemary oil (DB14689)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Essential oil solution
Study: 9786311
Drug: Prolonged infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prolonged infusion of 5-FU
Study: 16505413
Drug: Hepatic arterial
Normalized name: Sus scrofa artery preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hepatic arterial infusion (HAI)
Study: 9786311
Drug: Intravenous fluoropyrimidine-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous fluoropyrimidine-based therapies
Study: 8723583
Drug: Epoetin alfa
Normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epoetin alfa (300 IU/kg daily) for 14 or 9 days perioperatively, commencing 10 and 5 days preoperatively, respectively.
Study: 2182401
Drug: Cimetropium bromide
Normalized name: cimetropium bromide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetropium bromide (50 mg tid)
Study: 31086540
Drug: NIPPV in
Approvals — FDA: no, EMA: no, PMDA: no
Description: NIPPV in addition to medicines and oxygen therapy (Intervention Group-A)